Connect Biopharma (CNTB) Competitors $0.82 +0.01 (+1.43%) Closing price 04/30/2025 03:38 PM EasternExtended Trading$0.84 +0.02 (+2.00%) As of 09:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTB vs. INBX, ACTU, DERM, IPHA, HURA, TVGN, ACIU, MOLN, KRRO, and IKTShould you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include Inhibrx (INBX), Actuate Therapeutics (ACTU), Journey Medical (DERM), Innate Pharma (IPHA), TuHURA Biosciences (HURA), Tevogen Bio (TVGN), AC Immune (ACIU), Molecular Partners (MOLN), Korro Bio (KRRO), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. Connect Biopharma vs. Inhibrx Actuate Therapeutics Journey Medical Innate Pharma TuHURA Biosciences Tevogen Bio AC Immune Molecular Partners Korro Bio Inhibikase Therapeutics Inhibrx (NASDAQ:INBX) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends, analyst recommendations and community ranking. Do analysts rate INBX or CNTB? Connect Biopharma has a consensus price target of $8.00, suggesting a potential upside of 873.71%. Given Connect Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Connect Biopharma is more favorable than Inhibrx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, INBX or CNTB? Connect Biopharma has higher revenue and earnings than Inhibrx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibrx$200K892.45-$154.96MN/AN/AConnect Biopharma$24.12M1.89-$59.50MN/AN/A Does the media prefer INBX or CNTB? In the previous week, Inhibrx had 4 more articles in the media than Connect Biopharma. MarketBeat recorded 6 mentions for Inhibrx and 2 mentions for Connect Biopharma. Inhibrx's average media sentiment score of 1.69 beat Connect Biopharma's score of 0.30 indicating that Inhibrx is being referred to more favorably in the media. Company Overall Sentiment Inhibrx Very Positive Connect Biopharma Neutral Is INBX or CNTB more profitable? Connect Biopharma's return on equity of 0.00% beat Inhibrx's return on equity.Company Net Margins Return on Equity Return on Assets InhibrxN/A -113.74% -80.56% Connect Biopharma N/A N/A N/A Does the MarketBeat Community favor INBX or CNTB? Inhibrx received 12 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 73.08% of users gave Connect Biopharma an outperform vote while only 58.49% of users gave Inhibrx an outperform vote. CompanyUnderperformOutperformInhibrxOutperform Votes3158.49% Underperform Votes2241.51% Connect BiopharmaOutperform Votes1973.08% Underperform Votes726.92% Do institutionals and insiders believe in INBX or CNTB? 82.5% of Inhibrx shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 22.2% of Inhibrx shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryConnect Biopharma beats Inhibrx on 9 of the 14 factors compared between the two stocks. Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTB vs. The Competition Export to ExcelMetricConnect BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.48M$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.4422.5718.48Price / Sales1.89242.70395.64103.60Price / CashN/A65.8538.1834.62Price / Book0.456.516.774.25Net Income-$59.50M$143.21M$3.22B$248.23M7 Day Performance6.22%1.97%1.46%0.89%1 Month Performance43.59%6.89%3.98%3.53%1 Year Performance-42.55%-2.52%16.14%5.09% Connect Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTBConnect Biopharma2.5856 of 5 stars$0.82+1.4%$8.00+873.7%-40.9%$45.48M$24.12M0.00110INBXInhibrx2.552 of 5 stars$12.35+0.7%N/A-63.8%$178.78M$200,000.000.00166Short Interest ↓Positive NewsACTUActuate TherapeuticsN/A$9.05+1.1%$20.50+126.5%N/A$176.77MN/A0.0010DERMJourney Medical2.6451 of 5 stars$7.58+1.5%$9.88+30.3%+101.1%$175.13M$56.13M-8.0690Short Interest ↑News CoverageIPHAInnate Pharma2.5683 of 5 stars$2.09+5.5%$11.00+426.6%-3.5%$175.12M$12.63M0.00220Analyst RevisionHURATuHURA BiosciencesN/A$3.97-3.2%$12.67+219.1%N/A$173.41MN/A0.00N/ATVGNTevogen Bio3.0974 of 5 stars$0.94-5.5%$7.10+657.4%+3.0%$172.38MN/A0.003Analyst ForecastACIUAC Immune2.5414 of 5 stars$1.70+3.7%$12.00+605.9%-30.2%$170.70M$27.31M-3.70140Earnings ReportNews CoveragePositive NewsMOLNMolecular Partners2.4062 of 5 stars$4.08-2.9%$12.00+194.1%+3.1%$164.73M$4.97M-1.90180High Trading VolumeKRROKorro Bio1.4849 of 5 stars$17.47-3.4%$120.43+589.3%-68.7%$164.03M$2.27M-1.8670Analyst ForecastAnalyst RevisionNews CoveragePositive NewsIKTInhibikase Therapeutics1.5293 of 5 stars$2.20+4.3%$6.50+195.5%+53.7%$163.55M$260,000.00-0.826News CoveragePositive NewsGap Down Related Companies and Tools Related Companies INBX Competitors ACTU Competitors DERM Competitors IPHA Competitors HURA Competitors TVGN Competitors ACIU Competitors MOLN Competitors KRRO Competitors IKT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTB) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNTB Stock Free CNTB Stock Alerts